October 29, 2025 — Leads & Copy — Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) has signed a non-exclusive distribution agreement with PHALANX, Comercializadora e Importadora de Componentes SA DE CV (“Phalanx”), a company based in Mexico, to expand into the Mexican healthcare sector with barium-based contrast media.
The agreement, which follows a non-binding Letter of Intent announced on June 24, 2025, commits both companies to a strategic partnership. Phalanx will register Voyageur’s barium contrast media products with Mexican health regulatory authorities and distribute them through its established network. Voyageur will support Phalanx in regulatory approval, market access, and commercialization.
Phalanx, a pharmaceutical distributor in Mexico and Latin America, provides commercial intelligence and strategic market solutions. They specialize in market entry strategies, distribution, and business development in the health sector. With over 20 years of expertise in iodine and gadolinium contrast media, Phalanx aims to accelerate international expansion for global companies.
According to Voyageur CEO Brent Willis, this partnership expands Voyageur’s global footprint, providing access to underserved markets with a demand for high-quality contrast media, and is a key milestone in the company’s international growth strategy.
Brent Willis, CEO, Brent@vpharma.ca, 403-923-5944
Albert Deslauriers, CFO, Albert@vpharma.ca
Source: Voyageur Pharmaceuticals Ltd.
Source: Voyageur Pharmaceuticals Ltd.
